ABBV vs V: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Visa Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-29.
AbbVie Inc. · Healthcare
$197.69
+6.3% upside to fair value
Grade C
High Quality
VS
Visa Inc. · Financial Services
$304.36
+45.0% upside to fair value
High Conviction
Grade A-
QuantHub Verdict
V has more upside to fair value
(+45.0%).
V trades at a lower forward P/E
(23.7x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
V |
| Current Price |
$197.69 |
$304.36 |
| Fair Value Estimate |
$210.22 |
$441.32 |
| Upside to Fair Value |
+6.3%
|
+45.0%
|
| Market Cap |
$349.7B |
$586.8B |
| Forward P/E |
83.3x
|
23.7x
|
| EV / EBITDA |
23.4x
|
22.3x
|
| Price / Sales |
5.7x
|
14.2x
|
| Price / FCF |
18.7x
|
25.6x
|
| Revenue Growth YoY |
+10.0%
|
+11.3%
|
| Gross Margin |
70.2%
|
81.08%
|
| Operating Margin |
26.7%
|
59.18%
|
| Return on Equity |
-361.6%
|
54.22%
|
| Dividend Yield |
0% |
0.83% |
| FCF Yield |
5.35%
|
3.91%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
Visa is the world's dominant payment network with $40B in net revenue (FY2025), 50%+ net margins, and a capital-light toll-booth model processing $14.2T in annual payment volume across 257.5B transactions. The business compounds at 10-12% revenue CAGR with operating leverage pushing EPS growth to 12-15% over a cycle, funded by $21.6B in annual free cash flow against only $1.5B in capex. At 28.0x …
Accumulation Zones
| Metric |
ABBV |
V |
| Zone Low |
$157.66 |
$330.99 |
| Zone High |
$178.69 |
$375.12 |
| In Buy Zone? |
No
|
Yes
|